Physician profile
Rajeev Garg
NPI 1275624231
$21,640.09
in general payments reported to CMS, 2019-2025
52 companies · $2,208 in 2025
The $2,208 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,070 · 2020: $2,011 · 2021: $2,137 · 2022: $2,280 · 2023: $2,215 · 2024: $1,720 · 2025: $2,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,142.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $8,432.81 | 2019-2025 | Jot Dx, Assurity, Gallant |
| Boston Scientific Corporation | $1,926.68 | 2019-2025 | Rotapro, General - Therapies, Accolade Sr |
| Abiomed | $1,417.39 | 2019-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $1,355.67 | 2019-2025 | |
| Edwards Lifesciences Corporation | $972.09 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Merck Sharp & Dohme LLC | $835.03 | 2021-2025 | Verquvo, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $648.58 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $639.24 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $627.73 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $488.86 | 2020-2025 | Jardiance |
| Pfizer INC. | $478.26 | 2020-2025 | |
| Amgen INC. | $462.93 | 2019-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $296.91 | 2021-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $252.91 | 2019-2021 | |
| Medtronic, INC. | $241.79 | 2021-2025 | Corevalve Evolut R |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Garg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.